Biosite(R) Incorporated Announces Exclusive License for Cardiovascular Marker

Company Licenses Caspase-1 From Johannes Gutenberg University, Mainz, Germany 


SAN DIEGO, Aug. 22  /PRNewswire-FirstCall/ -- Biosite(R) Incorporated (NASDAQ:BSTE) today announced it has signed an exclusive license with Johannes Gutenberg University, Mainz, Germany for Caspase-1, a potentially important cardiovascular disease biomarker.

Under the terms of the license agreement, Biosite is collaborating with the University of Mainz to investigate possible clinical applications for the biomarker.  The financial terms of the agreement were not disclosed.

"Each year, cardiovascular diseases top the list of the country's most serious health problems, and although Biosite has commercialized products on the market addressing cardiovascular diseases, it is an important area of ongoing investigation for our Biosite Discovery program," said Gunars Valkirs, Ph.D., Biosite's senior vice president Biosite Discovery.

About Biosite Incorporated

Biosite Incorporated is a leading bio-medical company commercializing proteomics discoveries for the advancement of medical diagnosis.  The Company's products contribute to improvements in medical care by aiding physicians in the diagnosis of critical diseases and health conditions. Biosite's Triage(R) rapid diagnostics are used in approximately 50 percent of U.S. hospitals and in over 50 international markets.  Information on Biosite can be found at http://www.biosite.com/.

Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements.  Statements that are not historical facts, including but not limited to statements that are preceded by, followed by, or that include the words "will"; "believes"; "should"; "intends"; "anticipates"; "plans"; "expects"; "estimates"; or similar statements are forward-looking statements. Forward looking statements include statements about the possible clinical applications for caspase-1 in the field of cardiovascular diseases and Biosite's ability to evaluate the diagnostic utility of the target.  Risks that should be considered include risks and uncertainties regarding the discovery and product development process generally, risks associated with the introduction of competitive products from companies with greater capital and resources, uncertainties around the proprietary nature of the targets subject to the collaboration, expansion or development of a direct sales effort in domestic and international markets, and risks and expenses associated with litigation, contract disputes, patent conflicts, product recalls, manufacturing constraints, backlog, delays or inefficiencies, shipment problems, seasonal customer demand, the timing of significant orders, changes in reimbursement policies, regulatory changes, competitive pressures on average selling prices, and the other risks detailed in Biosite's most recent Annual Report on Form 10-K, as amended, and other SEC filings.  Biosite disclaims, any intent or obligation to update these forward-looking statements.  Copies of Biosite's public disclosure filings are available from its investor relations department.

Biosite(R), Triage(R) and New Dimensions in Diagnosis(R) are registered trademarks of Biosite Incorporated.  The Company's logo is a trademark of Biosite Incorporated. 

DATASOURCE: Biosite Incorporated



CONTACT:  Nadine Padilla, VP, Corporate & Investor Relations of Biosite

Incorporated, [phone], ext. 3187, 



Web site:  http://www.biosite.com/ 



Company News On-Call:  http://www.prnewswire.com/comp/116737.html 

Copyright